c-erbB-2的表达与非小细胞肺癌多药耐药的关系

目的探讨c-erbB-2基因表达和非小细胞肺癌的化疗耐药性的关系,初步明确c-erbB-2基因在介导非小细胞肺癌(NSCLC)耐药机制中的作用。方法应用MTT法对54例未经化疗的非小细胞肺癌进行体外化疗药物敏感性测试,观察非小细胞肺癌分别对环磷酰胺、阿霉素、顺铂+氟尿嘧啶三种单药和联合用药方案耐药情况;用免疫组织化学方法检测c-erbB-2基因的表达,并对其表达情况与对应的化疗耐药性进行相关分析。结果54例NSCLC化疗敏感性检测结果显示:32例(59.3%)对环磷酰胺耐药,31例(57.4%)对阿霉素耐药,25例(46.3%)对顺铂+氟尿嘧啶耐药。其中,11例(20.4%)对3种用药均敏感,16例(29.6%)对3种用药均耐药,其耐药性与组织学类型和分化程度无关(P>0.05)。c-erbB-2在54例非小细胞肺癌中总的阳性表达率为53.7%,其中鳞癌和腺癌相比c-erbB-2的表达无显著性差异(P>0.05)。c-erbB-2的表达与3种化疗用药的耐药性均呈显著正相关(P<0.05),并且不同表达程度间也有显著差异性(P<0.05)。结论c-erbB-2在非小细胞肺癌中有较高的阳性表达,其参与介导了NSCLC固有化疗耐药的机制。

Relationship betweent expession of c-erbB-2 and multidrug resistance in non-small cell lung cancer

Objective To investigate the relationship between the expression of c-erbB-2 and multidrug resisance(MDR)for chemotherapy in non-small cell lung cancer(NSCLC),and define the function of the c-erbB-2 gene in MDR mechanisms.Methods Forty NSCLC patients were tasted with MTT assay to evaluate their chemoresistance.The chemotherapy drugs include cyclophamide,adriamycin,and cisplatin plus fluorouracil.The expression of the c-erbB-2 gene was examined with immunohistochemical assay.Results The MDR percentage for cyclophamide,adriamycin,and cisplatin plus fluorouracil were 59.3%,57.4%,and 46.3%,respectively.There was 16 cases resisting all three medications,while there was 11 cases sensitizing for all three medications.The MDR was not associated with histological types and degree of differentiation of NSCLC.The expression percentage of the c-erbB-2 in NSCLC was 53.7%.There is not significant difference in the expression of c-erbB2 between adeoncarcinoma and sequamous cell arcinoma(P>0.05).The expression of c-erbB-2 had a parallel relationship with the degrees of chemoresistance in three kinds of agents(P<0.05),and the MDR degrees in three kinds of agents among the different degrees of expressions of c-erbB-2 were significantly different(P<0.05).Conclusion A higher positive expresion of c-erbB-2 is present in NSCLC patients,and the expresion of c-erbB-2 participates in the intrinsic MDR in NSCLC patients.